Sage Therapeutic Net Receivables Over Time
| SAGE Stock | USD 5.47 0.08 1.44% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Sage Therapeutic Performance and Sage Therapeutic Correlation. Sage |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share 1.76 | Quarterly Revenue Growth 3.371 | Return On Assets (0.30) | Return On Equity (0.49) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Receivables Analysis
Compare Sage Therapeutic and related stocks such as Apellis Pharmaceuticals, Terns Pharmaceuticals, and Day One Biopharmaceu Net Receivables Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APLS | 67.2 K | 67.2 K | 67.2 K | 67.2 K | 465.9 K | 1.8 M | 1.3 M | 1.3 M | 1.5 M | 25 M | 25 M | 10.1 M | 7.7 M | 206.4 M | 216.8 M |
| TERN | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 11.4 M | 10.2 M |
| BPMC | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.6 M | 215 K | 215 K | 23.4 M | 25.3 M | 37 M | 36.9 M | 43.2 M | 45.3 M |
| RLAY | 82.7 M | 82.7 M | 82.7 M | 82.7 M | 82.7 M | 82.7 M | 82.7 M | 82.7 M | 82.7 M | 82.7 M | 82.7 M | 4.9 M | 5.2 M | 0.0 | 0.0 |
| STOK | 196 K | 196 K | 196 K | 196 K | 196 K | 196 K | 196 K | 196 K | 196 K | 281 K | 6 K | 132 K | 588 K | 64 K | 60.8 K |
| PLRX | 250 K | 250 K | 250 K | 250 K | 250 K | 250 K | 250 K | 250 K | 500 K | 7.4 M | 9.4 M | 2 M | 2 M | 3 M | 3.8 M |
| ARVN | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 26 M | 5 M | 6.3 M | 1000 K | 25.7 M | 8 M | 7.2 M | 11.1 M |
| KRYS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 42 M | 23.1 M |
| ALNY | 1.2 M | 1.5 M | 104 K | 4.2 M | 39.9 M | 8.3 M | 23.3 M | 34 M | 18.8 M | 43 M | 102.4 M | 198.6 M | 238 M | 327.8 M | 344.2 M |
| MDGL | 16 M | 46.2 K | 46.2 K | 46.2 K | 46.2 K | 7.3 K | 7.3 K | 7.3 K | 7.3 K | 7.3 K | 7.3 K | 7.3 K | 7.3 K | 6.6 K | 6.3 K |
| INCY | 7.2 M | 6.4 M | 71 M | 35.4 M | 57.9 M | 114.5 M | 148.8 M | 266.3 M | 307.6 M | 308.8 M | 482 M | 616.3 M | 644.9 M | 743.6 M | 780.7 M |
| DMAC | 20 K | 50.4 K | 20.5 K | 14.3 K | 8.4 K | 9.6 K | 52 K | 80 K | 780 K | 823 K | 340 K | 130 K | 82 K | 369 K | 387.4 K |
| AKRO | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 417 K | 417 K | 479.6 K | 339.9 K |
| NUVL | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 4.5 M | 5.1 M | 4.2 M |
| IMCR | 11 M | 11 M | 11 M | 11 M | 11 M | 11 M | 11 M | 17.5 M | 46.1 M | 50 M | 2.1 M | 24.8 M | 27.8 M | 61.4 M | 33.1 M |
| VTYX | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 96 K | 800 K | 840 K |
Sage Therapeutic and related stocks such as Apellis Pharmaceuticals, Terns Pharmaceuticals, and Day One Biopharmaceu Net Receivables description
My Equities
My Current Equities and Potential Positions
| Sage Therapeutic | SAGE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 5.47
Check out Sage Therapeutic Performance and Sage Therapeutic Correlation. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Sage Therapeutic technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.